In8bio, INC.

Publicly traded New York company in biological products, (no diagnostic substances) (Nasdaq: INAB).[6]

Overview

In8bio, INC. is a publicly traded company listed on Nasdaq under the ticker INAB [2]. The company is classified by the SEC under SIC 2836, Biological Products (No Diagnostic Substances) [3]. In8bio maintains its headquarters at the Empire State Building, 350 Fifth Avenue, Suite 5330, New York, NY, 10118 [1]. The company was previously filed with the SEC under the name Incysus Therapeutics, Inc. between May 22, 2018 and September 20, 2018 [4]. According to its most recent annual report to the SEC, In8bio reported total assets of $32.3 million [5].

Business address: EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118. [1]

Business address: 350 5th Ave, New York, New York, 10118. [8]

Financials

Reported total assets of $32.3 million in its most recent annual report to the SEC. [5]

Financials

TickerNASDAQ: INABShare price1.33 USD
2026-091.33 USD-99% since 2021
2021-10low 1 · high 2282026-09

Market data, not a filing. Read 2026-09-30.

Something wrong or missing? Send an update. Fixed within 24 hours.